Read more

November 19, 2021
2 min read
Save

10-year MACCE after left main CAD revascularization does not differ by sex

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among patients with left main CAD, the incidence of MACCE was similar with coronary revascularization in male and female patients, according to 10-year results of the PRECOMBAT trial.

According to Yujin Yang, MD, of University of Ulsan College of Medicine in Seoul, South Korea, and colleagues, limited data exist on the long-term prognostic impact of sex and sex-treatment interactions in patients with left main CAD undergoing coronary revascularization. This led them to assess the long-term effects of sex and related differential outcomes after PCI or CABG in this patient population.

Interventional cardiologist in cath lab_Adobe Stock
Source: Adobe Stock

Yang and colleagues defined the primary outcome as MACCE — a composite of death, MI, stroke or ischemia-driven target vessel revascularization — at 10 years.

The study included 600 patients (77% men) with left main CAD who were randomly assigned to PCI with drug-eluting stents or CABG. Patients were enrolled from April 2004 to August 2009.

Compared with male patients, female patients had a lower proportion of current smokers (P < .001) and higher EuroSCORE (P <.001), whereas other clinical and anatomical characteristics were similar between the sexes.

In the overall cohort, 10-year rates of MACCE were similar between sexes (men, 27.3%; women, 27%; adjusted HR = 1.06; 95% CI, 0.7-1.59); similarly, these rates did not differ in the PCI arm (men, 30.6%; women, 27.1%; aHR = 1.19; 95% CI, 0.69-2.05) or the CABG arm (men, 24%; women, 26.9%; aHR = 0.93; 95% CI, 0.53-1.62).

Furthermore, the risks for MACCE at 10 years were similar between PCI and CABG in both male (aHR = 1.37; 95% CI, 0.95-1.97) and female (aHR = 1.07; 95% CI, 0.56-2.07) patients. Researchers also found no significant sex-treatment interaction in the adjusted risk for 10-year MACCE (P for interaction = .52).

“In this 10-year report of the PRECOMBAT trial, we did not find differential prognostic effects of sex on the long-term risk of MACCE,” Yang and colleagues wrote. “Moreover, the rates of MACCE were similar after PCI and CABG both in male and female subjects without a significant interaction between sex and the relative treatment effect. The prognostic value and clinical adaptation of the sex-specific factor in patients with [left main CAD] for use in coronary heart team discussions regarding the optimal revascularization strategy should be further validated in larger sized clinical studies in the contemporary revascularization setting.”